Trials / Conditions / Stage III Ureter Cancer AJCC v8

Stage III Ureter Cancer AJCC v8

10 registered clinical trials studyying Stage III Ureter Cancer AJCC v8.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in NCT05092958	National Cancer Institute (NCI)	Phase 3
Active Not Recruiting	Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or NCT04940299	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	ARID1A and/or KDM6A Mutation and CXCL13 Expression NCT04953104	M.D. Anderson Cancer Center	Phase 2
Terminated	Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary NCT04398368	Mayo Clinic	Phase 2
Completed	Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial C NCT03513952	National Cancer Institute (NCI)	Phase 2
Completed	Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Partici NCT03617913	Mayo Clinic	Phase 2
Completed	Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies NCT03590054	Rahul Aggarwal	Phase 1
Active Not Recruiting	Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metasta NCT03237780	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourin NCT02496208	National Cancer Institute (NCI)	Phase 1
Completed	Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer NCT00749892	M.D. Anderson Cancer Center	Phase 2